Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells $15,570.00 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 1,038 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $15.00, for a total value of $15,570.00. Following the transaction, the chief executive officer directly owned 429,667 shares in the company, valued at $6,445,005. This represents a 0.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

KalVista Pharmaceuticals Trading Down 0.4%

Shares of KALV opened at $15.83 on Friday. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $9.23 and a fifty-two week high of $19.00. The business has a 50-day moving average of $15.50 and a 200 day moving average of $13.89. The firm has a market cap of $800.21 million, a P/E ratio of -4.01 and a beta of -0.19. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Invesco Ltd. raised its position in shares of KalVista Pharmaceuticals by 23.1% in the fourth quarter. Invesco Ltd. now owns 77,864 shares of the specialty pharmaceutical company’s stock worth $1,258,000 after buying an additional 14,621 shares in the last quarter. XTX Topco Ltd bought a new position in KalVista Pharmaceuticals in the 4th quarter worth about $428,000. Vestal Point Capital LP raised its holdings in shares of KalVista Pharmaceuticals by 152.0% in the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after acquiring an additional 1,140,000 shares in the last quarter. Virtus Investment Advisers LLC boosted its position in shares of KalVista Pharmaceuticals by 364.9% during the 4th quarter. Virtus Investment Advisers LLC now owns 40,414 shares of the specialty pharmaceutical company’s stock valued at $653,000 after acquiring an additional 31,721 shares during the last quarter. Finally, Squadron Capital Management LLC bought a new stake in shares of KalVista Pharmaceuticals during the 4th quarter valued at about $11,305,000.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on KALV shares. TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Citigroup reissued a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. HC Wainwright raised their price target on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Needham & Company LLC increased their price objective on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.40.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.